TGA suspends seasonal flu immunization in children pending investigation of Western Australian reports of adverse reactions

26 April 2010

Australia's Therapeutic Goods Administration (TGA) is investigating reports of an increase in adverse events to the seasonal flu vaccine in Western Australia where all children six months to five years have been offered a free seasonal flu vaccination.

The pattern and rate of adverse reactions reported by WA have not been seen in other states, and the TGA will test batches of the vaccine used in WA for any abnormalities. Other states and territories seasonal flu vaccination programs have focused on individuals in high risk categories.

The TGA is investigating the WA data to determine whether the adverse reactions reported there relate to the vaccine, or the WA program delivery. However, until it can be established what is causing the rise in adverse events in some children in WA, Australia's Chief Medical Officer, Professor Jim Bishop, is writing to all immunization providers to advise them not to administer seasonal flu vaccinations to all children five years of age and under until further notice.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Pharmaceutical